BioSpace

UCB captures Candid in $2.2B autoimmune deal as pharma’s M&A train chugs along

Candid Therapeutics follows closely behind Neurona Therapeutics, which UCB acquired in mid-April in a potential $1.15 billion ...
Rutland Herald

UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers

UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology ...
Morningstar

Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases

T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalities Cizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseases Over 60 ...